| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.08 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.073 | 0.09 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.09 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.09 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.09 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | 0.21 | 0.09 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.054 | 0.09 |